Comments
Loading...

10x Genomics Analyst Ratings

TXGNASDAQ
Logo brought to you by Benzinga Data
Consensus Rating1
Neutral
Highest Price Target1
$60.00
Lowest Price Target1
$6.50
Consensus Price Target1
$23.79

10x Genomics Analyst Ratings and Price Targets | NASDAQ:TXG | Benzinga

10x Genomics Inc has a consensus price target of $23.79 based on the ratings of 20 analysts. The high is $60 issued by Goldman Sachs on July 14, 2022. The low is $6.5 issued by Goldman Sachs on May 12, 2025. The 3 most-recent analyst ratings were released by Morgan Stanley, Stephens & Co., and UBS on May 19, 2025, May 15, 2025, and May 13, 2025, respectively. With an average price target of $14.67 between Morgan Stanley, Stephens & Co., and UBS, there's an implied 53.26% upside for 10x Genomics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Jan
6
3
Feb
1
Mar
1
Apr
3
2
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.4
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Morgan Stanley
Stephens & Co.
UBS
Goldman Sachs
Canaccord Genuity

1calculated from analyst ratings

Analyst Ratings for 10x Genomics

Buy NowGet Alert
05/19/2025Buy Now88.09%Morgan Stanley
Tejas Savant50%
$26 → $18MaintainsOverweightGet Alert
05/15/2025Buy Now46.29%Stephens & Co.
Mason Carrico41%
$14 → $14ReiteratesOverweight → OverweightGet Alert
05/13/2025Buy Now25.39%UBS
Dan Leonard54%
$14 → $12MaintainsNeutralGet Alert
05/12/2025Buy Now-32.08%Goldman Sachs
Matthew Sykes64%
$7.5 → $6.5MaintainsSellGet Alert
05/12/2025Buy Now56.74%Canaccord Genuity
Kyle Mikson39%
$18 → $15MaintainsBuyGet Alert
05/09/2025Buy Now-5.96%JP Morgan
Rachel Vatnsdal66%
$12 → $9MaintainsNeutralGet Alert
04/10/2025Buy Now25.39%Barclays
Luke Sergott50%
$15 → $12MaintainsOverweightGet Alert
03/04/2025Buy Now56.74%Citigroup
Patrick Donnelly80%
$20 → $15MaintainsBuyGet Alert
02/14/2025Buy Now171.68%Morgan Stanley
Tejas Savant50%
$28 → $26MaintainsOverweightGet Alert
02/14/2025Buy Now56.74%Barclays
Luke Sergott50%
$18 → $15MaintainsOverweightGet Alert
02/13/2025Buy Now88.09%Canaccord Genuity
Kyle Mikson39%
$20 → $18MaintainsBuyGet Alert
02/13/2025Buy Now108.99%Citigroup
Patrick Donnelly80%
$23 → $20MaintainsBuyGet Alert
02/13/2025Buy Now25.39%JP Morgan
Rachel Vatnsdal66%
$14 → $12MaintainsNeutralGet Alert
02/13/2025Buy Now46.29%UBS
Dan Leonard54%
$20 → $14MaintainsNeutralGet Alert
02/13/2025Buy Now88.09%Stifel
Daniel Arias78%
$21 → $18MaintainsBuyGet Alert
02/13/2025Buy Now25.39%Leerink Partners
Mike Kratky66%
$25 → $12DowngradeOutperform → Market PerformGet Alert
02/10/2025Buy Now88.09%Barclays
Luke Sergott50%
$19 → $18MaintainsOverweightGet Alert
01/13/2025Buy Now192.58%Morgan Stanley
Tejas Savant50%
$30 → $28MaintainsOverweightGet Alert
11/01/2024Buy Now98.54%Barclays
Luke Sergott50%
$21 → $19MaintainsOverweightGet Alert
10/30/2024Buy Now140.33%Citigroup
Patrick Donnelly80%
$35 → $23MaintainsBuyGet Alert
10/30/2024Buy Now46.29%Goldman Sachs
Matthew Sykes64%
$16 → $14MaintainsSellGet Alert
10/30/2024Buy Now46.29%JP Morgan
Rachel Vatnsdal66%
$20 → $14MaintainsNeutralGet Alert
10/30/2024Buy Now108.99%UBS
Dan Leonard54%
$25 → $20MaintainsNeutralGet Alert
10/15/2024Buy Now119.44%Barclays
Luke Sergott50%
$24 → $21MaintainsOverweightGet Alert
10/10/2024Buy Now213.48%Stephens & Co.
Mason Carrico41%
$30 → $30ReiteratesOverweight → OverweightGet Alert
10/10/2024Buy Now108.99%Canaccord Genuity
Kyle Mikson39%
$32 → $20MaintainsBuyGet Alert
09/04/2024Buy Now213.48%Stephens & Co.
Mason Carrico41%
$30 → $30ReiteratesOverweight → OverweightGet Alert
09/03/2024Buy Now265.73%Leerink Partners
Mike Kratky66%
→ $35Initiates → OutperformGet Alert
08/13/2024Buy Now161.23%UBS
Dan Leonard54%
$30 → $25MaintainsNeutralGet Alert
08/13/2024Buy Now380.67%Morgan Stanley
Tejas Savant50%
$50 → $46MaintainsOverweightGet Alert
07/23/2024Buy Now234.38%Canaccord Genuity
Kyle Mikson39%
$50 → $32MaintainsBuyGet Alert
07/22/2024Buy Now150.78%Jefferies
Tycho Peterson82%
$24 → $24UpgradeHold → BuyGet Alert
07/18/2024Buy Now161.23%B of A Securities
Derik De Bruin84%
$36 → $25MaintainsNeutralGet Alert
07/18/2024Buy Now108.99%JP Morgan
Rachel Vatnsdal66%
$40 → $20DowngradeOverweight → NeutralGet Alert
07/16/2024Buy Now161.23%Stifel
Daniel Arias78%
$53 → $25MaintainsBuyGet Alert
07/10/2024Buy Now161.23%Deutsche Bank
Justin Bowers46%
$55 → $25DowngradeBuy → HoldGet Alert
07/09/2024Buy Now67.19%Goldman Sachs
Matthew Sykes64%
$26 → $16MaintainsSellGet Alert
06/28/2024Buy Now150.78%Barclays
Luke Sergott50%
$36 → $24MaintainsOverweightGet Alert
06/27/2024Buy NowWolfe Research
Doug Schenkel71%
DowngradeOutperform → Peer PerformGet Alert
06/26/2024Buy NowGuggenheim
Subbu Nambi46%
DowngradeBuy → NeutralGet Alert
06/25/2024Buy NowGuggenheim
Subbu Nambi46%
DowngradeBuy → NeutralGet Alert
06/03/2024Buy Now150.78%Jefferies
Tycho Peterson82%
→ $24Initiates → HoldGet Alert
05/01/2024Buy Now213.48%UBS
Dan Leonard54%
$52 → $30MaintainsNeutralGet Alert
05/01/2024Buy Now276.18%B of A Securities
Derik De Bruin84%
$45 → $36MaintainsNeutralGet Alert
05/01/2024Buy Now171.68%Goldman Sachs
Matthew Sykes64%
$30 → $26MaintainsSellGet Alert
05/01/2024Buy Now234.38%TD Cowen
Dan Brennan62%
$57 → $32DowngradeBuy → HoldGet Alert
05/01/2024Buy Now453.81%Stifel
Daniel Arias78%
$63 → $53MaintainsBuyGet Alert
04/29/2024Buy Now422.47%Canaccord Genuity
Kyle Mikson39%
$65 → $50MaintainsBuyGet Alert
04/18/2024Buy Now474.71%Deutsche Bank
Justin Bowers46%
$60 → $55MaintainsBuyGet Alert
04/10/2024Buy Now370.22%Barclays
Luke Sergott50%
$55 → $45MaintainsOverweightGet Alert
02/16/2024Buy Now558.31%Stifel
Daniel Arias78%
$68 → $63MaintainsBuyGet Alert
01/25/2024Buy Now474.71%Barclays
Luke Sergott50%
$45 → $55MaintainsOverweightGet Alert
12/14/2023Buy Now526.96%Guggenheim
Subbu Nambi46%
→ $60Initiates → BuyGet Alert
12/13/2023Buy NowWolfe Research
Doug Schenkel71%
Initiates → OutperformGet Alert
12/12/2023Buy Now464.26%B of A Securities
Derik De Bruin84%
$36 → $54UpgradeUnderperform → NeutralGet Alert
09/29/2023Buy Now391.12%Barclays
Luke Sergott50%
$66 → $47MaintainsOverweightGet Alert
09/19/2023Buy Now631.45%Canaccord Genuity
Kyle Mikson39%
→ $70ReiteratesBuy → BuyGet Alert
08/07/2023Buy Now579.21%Morgan Stanley
Tejas Savant50%
$65 → $65ReiteratesOverweight → OverweightGet Alert
08/04/2023Buy Now589.66%Barclays
Luke Sergott50%
$65 → $66MaintainsOverweightGet Alert
08/04/2023Buy Now683.7%Citigroup
Patrick Donnelly80%
$65 → $75MaintainsBuyGet Alert
07/13/2023Buy Now213.48%Goldman Sachs
Matthew Sykes64%
$25 → $30MaintainsSellGet Alert
05/18/2023Buy Now579.21%Stephens & Co.
Mason Carrico41%
→ $65ReiteratesOverweight → OverweightGet Alert
05/10/2023Buy Now579.21%Barclays
Luke Sergott50%
→ $65Initiates → OverweightGet Alert
05/04/2023Buy Now610.55%Stifel
Daniel Arias78%
$57 → $68MaintainsBuyGet Alert
05/04/2023Buy Now589.66%TD Cowen
Dan Brennan62%
$62 → $66MaintainsOutperformGet Alert
05/04/2023Buy Now579.21%Canaccord Genuity
Kyle Mikson39%
$58 → $65MaintainsBuyGet Alert
05/04/2023Buy Now579.21%Stephens & Co.
Mason Carrico41%
→ $65Reiterates → OverweightGet Alert
03/31/2023Buy Now579.21%Stephens & Co.
Mason Carrico41%
→ $65Initiates → OverweightGet Alert
02/16/2023Buy Now579.21%Morgan Stanley
Tejas Savant50%
$64 → $65MaintainsOverweightGet Alert
02/16/2023Buy Now506.06%Canaccord Genuity
Kyle Mikson39%
$55 → $58MaintainsBuyGet Alert
02/16/2023Buy Now495.61%Cowen & Co.
Dan Brennan62%
$52 → $57MaintainsOutperformGet Alert
02/02/2023Buy Now422.47%UBS
John Sourbeer30%
→ $50Initiates → NeutralGet Alert
12/14/2022Buy Now422.47%Deutsche Bank
Justin Bowers46%
→ $50Initiates → BuyGet Alert
11/04/2022Buy Now568.76%Morgan Stanley
Tejas Savant50%
$70 → $64MaintainsOverweightGet Alert
10/13/2022Buy Now161.23%Goldman Sachs
Matthew Sykes64%
$35 → $25MaintainsSellGet Alert
08/18/2022Buy Now265.73%Goldman Sachs
Matthew Sykes64%
$55 → $35DowngradeNeutral → SellGet Alert
08/10/2022Buy Now631.45%Morgan Stanley
Tejas Savant50%
$100 → $70MaintainsOverweightGet Alert
07/15/2022Buy Now422.47%Cowen & Co.
Dan Brennan62%
$90 → $50MaintainsOutperformGet Alert
07/15/2022Buy Now265.73%B of A Securities
Derik De Bruin84%
$80 → $35DowngradeNeutral → UnderperformGet Alert
07/15/2022Buy NowWilliam Blair
Brian Weinstein27%
DowngradeOutperform → Market PerformGet Alert
07/14/2022Buy Now526.96%Goldman Sachs
Amit Hazan55%
$80 → $60MaintainsNeutralGet Alert

FAQ

Q

What is the target price for 10x Genomics (TXG) stock?

A

The latest price target for 10x Genomics (NASDAQ:TXG) was reported by Morgan Stanley on May 19, 2025. The analyst firm set a price target for $18.00 expecting TXG to rise to within 12 months (a possible 88.09% upside). 41 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for 10x Genomics (TXG)?

A

The latest analyst rating for 10x Genomics (NASDAQ:TXG) was provided by Morgan Stanley, and 10x Genomics maintained their overweight rating.

Q

When was the last upgrade for 10x Genomics (TXG)?

A

The last upgrade for 10x Genomics Inc happened on July 22, 2024 when Jefferies raised their price target to $24. Jefferies previously had a hold for 10x Genomics Inc.

Q

When was the last downgrade for 10x Genomics (TXG)?

A

The last downgrade for 10x Genomics Inc happened on February 13, 2025 when Leerink Partners changed their price target from $25 to $12 for 10x Genomics Inc.

Q

When is the next analyst rating going to be posted or updated for 10x Genomics (TXG)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 10x Genomics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 10x Genomics was filed on May 19, 2025 so you should expect the next rating to be made available sometime around May 19, 2026.

Q

Is the Analyst Rating 10x Genomics (TXG) correct?

A

While ratings are subjective and will change, the latest 10x Genomics (TXG) rating was a maintained with a price target of $26.00 to $18.00. The current price 10x Genomics (TXG) is trading at is $9.57, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch